JP3119961B2 - Stratum corneum turnover speed improver - Google Patents
Stratum corneum turnover speed improverInfo
- Publication number
- JP3119961B2 JP3119961B2 JP05066214A JP6621493A JP3119961B2 JP 3119961 B2 JP3119961 B2 JP 3119961B2 JP 05066214 A JP05066214 A JP 05066214A JP 6621493 A JP6621493 A JP 6621493A JP 3119961 B2 JP3119961 B2 JP 3119961B2
- Authority
- JP
- Japan
- Prior art keywords
- stratum corneum
- yeast
- turnover speed
- skin
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000007306 turnover Effects 0.000 title claims description 23
- 210000000434 stratum corneum Anatomy 0.000 title claims description 19
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 239000012138 yeast extract Substances 0.000 claims description 10
- 229960002298 aminohydroxybutyric acid Drugs 0.000 claims description 9
- YQGDEPYYFWUPGO-UHFFFAOYSA-N gamma-amino-beta-hydroxybutyric acid Chemical compound [NH3+]CC(O)CC([O-])=O YQGDEPYYFWUPGO-UHFFFAOYSA-N 0.000 claims description 9
- 229940041514 candida albicans extract Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 210000003491 skin Anatomy 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 210000005253 yeast cell Anatomy 0.000 description 4
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000035404 Autolysis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CXHWYWOWOTYHEU-UHFFFAOYSA-K [OH-].[OH-].[OH-].[Mg+2].[K+] Chemical compound [OH-].[OH-].[OH-].[Mg+2].[K+] CXHWYWOWOTYHEU-UHFFFAOYSA-K 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 201000002676 cerebral atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は、角質層のターンオーバ
ー速度改善剤に関する。BACKGROUND OF THE INVENTION The present invention relates to a stratum corneum turnover.
-It relates to a speed improver .
【０００２】[0002]
【従来の技術および発明が解決しようとする課題】老化
皮膚とは、乾燥して滑らかさのない荒れ肌で、角質細胞
剥離現象が認められる皮膚である。そして老化皮膚は、
ターンオーバー速度が遅く、また皮膚に老化防止効果が
付与発現するとターンオーバー速度が早くなると言われ
ている。特許第１５２７１３６号公報にはγ−アミノ−
β−ヒドロキシ酪酸が、皮膚の末梢血管拡張作用により
皮膚機能を亢進し、老化防止効果を有することが開示さ
れている。2. Description of the Related Art Aged skin is rough skin that is dry and has no smoothness and in which keratinocyte exfoliation is observed. And aging skin,
It is said that the turnover speed is low when the skin has an anti-aging effect, and the turnover speed is high. Japanese Patent No. 1527136 discloses γ-amino-
It is disclosed that β-hydroxybutyric acid enhances skin function by peripheral vasodilatory action of the skin and has an antiaging effect.
【０００３】しかし、γ−アミノ−β−ヒドロキシ酪酸
を単独で配合してなる皮膚化粧料はいずれも老化防止等
の効果は遅効性で、例えばクリームの場合では連用６ケ
月後に、ローションの場合は同様に８か月後に効果が現
れるというように、充分満足し得るものではなく、改良
の余地を残しているのが実情であった。[0003] However, all skin cosmetics containing γ-amino-β-hydroxybutyric acid alone have a long-acting effect of preventing aging and the like. Similarly, it was not satisfactory enough to show an effect after eight months, and there was room for improvement.
【０００４】一方、酵母の保湿効果もしくは皮膚美容効
果を利用して化粧料を配合することは公知であって、例
えば酵母菌体そのものをパックに用いた特公昭３９−４
８９９等がある。しかしながらこれらを単独で使用した
場合、これらの保水力により水分を保持し、皮膚に適度
の潤いを与える程度のもので、積極的に皮膚の老化防止
効果が得られるものではなかった。[0004] On the other hand, it is known to blend cosmetics utilizing the moisturizing effect or skin cosmetic effect of yeast, and for example, Japanese Patent Publication No. 39-4 using yeast cells themselves in a pack.
899 etc. However, when these are used alone, they retain water by their water retention ability and give the skin an appropriate amount of moisture, and do not actively obtain the effect of preventing skin aging.
【０００５】本発明者、このような実情に鑑み鋭意研究
した結果、γ−アミノ−β−ヒドロキシ酪酸（以下ＧＡ
ＢＯＢと略記する）及びその塩の少なくとも一種と、酵
母及び／又は酵母抽出物とからなる角質層のターンオー
バー速度改善剤は、これらの成分の相乗効果により、タ
ーンオーバー速度を早くする効果に優れることを見出し
本発明を完成するに至った。[0005] The present inventors have conducted intensive studies in view of such circumstances, and as a result, have found that γ-amino-β-hydroxybutyric acid (hereinafter referred to as GA).
Abbreviated as BOB) and at least one salt thereof, Tan'o of the horny layer composed of the yeast and / or yeast extract
Bar speed improvers, the synergistic effect of these components, data
It has been found that the effect of increasing the turnover speed is excellent, and the present invention has been completed.
【０００６】[0006]
【課題を解決するための手段】上記の目的を達成するた
めの本発明の角質層のターンオーバー速度改善剤は、Ｇ
ＡＢＯＢ及びその塩の少なくとも一種０．０１〜２質量
％と、酵母及び／又は酵母抽出物０．００１〜２０質量
％とからなる。To achieve the above object, the stratum corneum turnover speed improving agent of the present invention is G
And ABOB and at least one 0.01-2 mass <br/>% of a salt thereof, that Do from yeast and / or yeast extract 0.001 mass <br/>%.
【０００７】本発明に用いられるＧＡＢＯＢは公知の物
質であって、脳動脈硬化症の治療剤として適用されてお
り、その化学特性は下記の通りである。[0007] GABOB used in the present invention is a known substance and has been applied as a therapeutic agent for cerebral atherosclerosis, and its chemical properties are as follows.
【０００８】化学名：γ−アミノ−β−ヒドロキシ酪酸 （γ−ａｍｉｎｏ−β−ｈｙｄｏｒｘｙ ｂｕｔｙｒｉ
ｃ ａｃｉｄ） 分子式：Ｃ 4 Ｈ 9 ＮＯ 3 分子量：１１９．１２ 融点 ：２０５〜２１０℃Chemical name: γ-amino-β-hydroxybutyric acid (γ-amino-β-hydroxy butyri)
c acid) Molecular formula: C 4 H 9 NO 3 Molecular weight: 119.12 Melting point: 205-210 ° C.
【０００９】尚、特許第１５２７１３６号公報には、Ｇ
ＡＢＯＢは、皮膚組織賦活作用による皮膚老化防止効果
を有することが記載されている。Japanese Patent No. 1527136 discloses G
It is described that ABOB has an effect of preventing skin aging by activating skin tissue.
【００１０】ＧＡＢＯＢを苛性カリ、苛性ソーダ又は水
酸化カルシウム、水酸化マグネシウムで中和したＧＡＢ
ＯＢのカリウム塩、同ナトリウム塩、同カルシウム塩、
同マグネシウム塩はいずれも遊離型のＧＡＢＯＢと同程
度のターンオーバー速度改善効果を有する。GAB obtained by neutralizing GABOB with caustic potash, caustic soda or calcium hydroxide or magnesium hydroxide
Potassium salt, sodium salt, calcium salt of OB,
Any same magnesium salt also that have a turnover rate improvement effect comparable to GABOB of free.
【００１１】ＧＡＢＯＢ及びその塩の少なくとも一種の
配合量は、角質層のターンオーバー速度改善剤の全量を
基準として０．０１〜２質量％（以下、ｗｔ％と略記す
る）である。これらの各々の配合量の上限を越えても、
その越えた配合量に見合った効果は期待できず、また下
限未満の配合量では本発明の目的を達成することができ
ない。[0011] GABOB and at least one of the amount of a salt thereof, 0.01 to 2 mass% of the total amount of the turnover rate improving agent of the stratum corneum as a reference (hereinafter, abbreviated as wt%). Even if it exceeds the upper limit of the amount of each of these,
An effect commensurate with the compounding amount exceeding the above amount cannot be expected, and the object of the present invention cannot be achieved with a compounding amount below the lower limit.
【００１２】本発明に用いられる酵母、酵母抽出物には
酵母生菌体そのもの、酵母菌体を乾燥粉末化したもの及
び酵母菌体を自己消化、熱水抽出、酸加水分解、酵素分
解等の適当な条件下で可溶化、抽出、精製等を行った酵
母エキス等がある。酵母には一般にビール酵母、パン酵
母等Ｓａｃｃｈａｒａｍｙｃｅｓ属その他があり、また
酵母抽出物を得る場合、菌体の破壊処理として物理的、
化学的、生化学的方法が適用される。本発明には、原料
となる菌体種、起源や抽出方法、精製法、処理方法等の
製造方法を問わず、任意に選択、使用出来る。中でも、
市販されている酵母の乾燥粉末、酵母エキスが扱い易
く、また容易に入手でき便利である。 上記の酵母や酵
母抽出物には、蛋白質、脂質、無機塩、有機酸、ビタミ
ン、アミノ酸、糖質、核酸関連物質等有用な成分が含ま
れている。The yeast and yeast extract used in the present invention include live yeast cells themselves, dried and powdered yeast cells, and autolysis, hot water extraction, acid hydrolysis, and enzymatic decomposition of yeast cells. There are yeast extracts and the like that have been solubilized, extracted, purified, etc. under appropriate conditions. Yeasts generally include genus Saccharamyces and the like such as brewer's yeast and baker's yeast, and when obtaining a yeast extract, physically, as a destruction treatment of the cells,
Chemical and biochemical methods are applied. In the present invention, it can be arbitrarily selected and used irrespective of a production method such as a bacterial cell species as a raw material, an origin, an extraction method, a purification method, a treatment method and the like. Among them,
Commercially available dry powders and yeast extracts of yeast are easy to handle, easily available, and convenient. The above-described yeast and yeast extract contain useful components such as proteins, lipids, inorganic salts, organic acids, vitamins, amino acids, carbohydrates, and nucleic acid-related substances.
【００１３】酵母、酵母抽出物の配合量は、角質層のタ
ーンオーバー速度改善剤の全量を基準として０．０００
１〜２０ｗｔ％である。これらの各々の配合量の上限を
越えても、その越えた配合量に見合った効果は期待でき
ず、また下限未満の配合量では本発明の目的を達成する
ことができない。[0013] Yeast, the amount of yeast extract, the stratum corneum data
0.000 based on the total amount of turnover speed improver
1 to 20 wt%. Even if the amount exceeds the upper limit of each of these amounts, an effect commensurate with the exceeded amount cannot be expected, and if the amount is less than the lower limit, the object of the present invention cannot be achieved.
【００１４】尚、本発明の角質層のターンオーバー速度
改善剤には上記の他に色素，香料，防腐剤，界面活性
剤，顔料，抗酸化剤、ｐＨ調製剤、増粘剤等を本発明の
目的を達成する範囲内で適宜配合することができる。 The turnover speed of the stratum corneum of the present invention
In addition to the above, pigments, fragrances, preservatives, surfactants, pigments, antioxidants, pH adjusters, thickeners, and the like can be appropriately added to the improver within a range that achieves the object of the present invention. .
【００１５】本発明の角質層のターンオーバー速度改善
剤は、例えば、ローション類，乳液類，クリーム類，パ
ック類等に適用することができる。[0015] Improvement of turnover speed of stratum corneum of the present invention
The agent can be applied to, for example, lotions, emulsions, creams, packs, and the like.
【００１６】[0016]
【実施例】以下、実施例及び比較例に基づいて本発明を
詳細に説明する。尚、実施例に記載の角質層のターン
オーバー速度測定方法は下記の通りである。なお、ＧＡ
ＢＯＢのカリウム塩、ナトリウム塩、カルシウム塩、マ
グネシウム塩はそれぞれＧＡＢＯＢ−Ｋ，ＧＡＢＯＢ−
Ｎａ，ＧＡＢＯＢ−Ｃａ，ＧＡＢＯＢ−Ｍｇと略記す
る。The present invention will be described below in detail based on examples and comparative examples. The method of measuring the turnover speed of the stratum corneum described in the examples is as follows. Note that GA
The potassium, sodium, calcium, and magnesium salts of BOB are GABOB-K, GABOB-
Abbreviated as Na, GABOB-Ca, GABOB-Mg.
【００１７】角質層のターンオーバー速度の測定方法 蛍光色素のダンシルクロリドを白色ワセリン中に５ｗｔ
％配合した軟膏を作り、被験者の前腕部の皮膚に２４時
間閉塞塗布し、角質層にダンシルクロリドを浸透結合さ
せる。その後同じ部位に１日２回（朝、夕）被験試料を
塗布し、毎日ダンシルクロリドの蛍光をしらべ、その蛍
光が消滅するまでの日数を皮膚角質層のターンオーバー
速度とした。尚、通常の皮膚角質層のターンオーバー速
度は、１４〜１６日であるが、老化した皮膚においては
１８日前後に伸びる。それに対して老化防止効果が現れ
ると１２日前後にまで短縮される。Method for measuring the turnover rate of the stratum corneum The fluorescent dye dansyl chloride was added to white vaseline in an amount of 5 wt.
% Ointment is prepared, and occlusively applied to the skin of the forearm of the subject for 24 hours to allow dansyl chloride to penetrate into the stratum corneum. Thereafter, the test sample was applied to the same site twice a day (morning and evening), the fluorescence of dansyl chloride was examined every day, and the number of days until the fluorescence disappeared was defined as the turnover speed of the stratum corneum of the skin. In addition, the turnover speed of the normal skin stratum corneum is 14 to 16 days, but it extends around 18 days in aged skin. On the other hand, when the anti-aging effect appears, it is reduced to around 12 days.
【００１８】 実施例１〜５，比較例１〜５角質層のターンオーバー速度改善剤として、 ＧＡＢＯＢ
及びその塩の少なくとも一種と、酵母、酵母抽出物の配
合量及び組成を表１及び表２に示す。 [0018] Examples 1-5, as turnover rate improving agent of Comparative Examples 1 to 5 the stratum corneum, GABOB
And indicating at least one of its salts, yeast, amount and set configuration of yeast extract in Table 1 and Table 2.
【００１９】[0019]
【表１】 [Table 1]
【００２０】[0020]
【表２】 [Table 2]
【００２１】（２）調製法 （Ａ）成分及び（Ｂ）成分を各々８０℃に加熱溶解した
後混合して、攪拌しつつ冷却し、約５０℃にて（Ｃ）を
投入し、３０℃まで冷却して、角質層のターンオーバー
速度改善剤を調製した。 [0021] (2) were mixed after dissolved by heating Preparation of component (A) and component (B), respectively 80 ° C., stirring was cooled, poured at about 50 ° C. to (C), 30 ° C. Cool down to turn over the stratum corneum
A speed improver was prepared.
【００２２】 （３）特性 各角質層のターンオーバー速度改善剤の諸試験を実施し
た結果を表３、表４に記載した。 [0022] (3) Characteristics Table 3 the results of embodying test turnover rate improving agent of the stratum corneum, as described in Table 4.
【００２３】 [0023]
【００２４】表３に示すごとく、本発明の実施例１〜５
の角質層のターンオーバー速度改善剤は、比較例１〜５
に対して、角質層のターンオーバー速度の改善において
顕著な効果を示した。 As shown in Table 3 , Examples 1 to 5 of the present invention
The turnover speed improver of the stratum corneum of Comparative Examples 1 to 5
To improve the stratum corneum turnover speed
It showed a remarkable effect.
【００２５】[0025]
【発明の効果】以上記載のごとく、本発明が、角質層の
ターンオーバー速度を改善する効果に優れた、角質層の
ターンオーバー速度改善剤を提供することは明らかであ
る。As above described, according to the present invention, the present invention, the stratum corneum
Excellent in improving the turnover speed,
Obviously, a turnover speed improver is provided.
Claims (1)
の塩の少なくとも一種０．０１〜２質量％と、酵母及び
／又は酵母抽出物０．０００１〜２０質量％とからなる
角質層のターンオーバー速度改善剤。 Consisting of at least one 0.01-2 mass% of claim 1] γ- amino -β- hydroxybutyric acid and its salts, yeast and / or yeast extract 0.0001 mass%
Turnover speed improver for stratum corneum .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05066214A JP3119961B2 (en) | 1993-03-01 | 1993-03-01 | Stratum corneum turnover speed improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP05066214A JP3119961B2 (en) | 1993-03-01 | 1993-03-01 | Stratum corneum turnover speed improver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06256155A JPH06256155A (en) | 1994-09-13 |
| JP3119961B2 true JP3119961B2 (en) | 2000-12-25 |
Family
ID=13309357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP05066214A Expired - Fee Related JP3119961B2 (en) | 1993-03-01 | 1993-03-01 | Stratum corneum turnover speed improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3119961B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3877914B2 (en) * | 1999-09-07 | 2007-02-07 | サンスター株式会社 | Skin cosmetics |
| US20040028697A1 (en) * | 2000-07-08 | 2004-02-12 | Gilles Pauly | Method for protecting the skin from aging |
| JP2002193782A (en) * | 2000-12-22 | 2002-07-10 | Shiyuu Uemura Keshohin:Kk | Skin cosmetic |
-
1993
- 1993-03-01 JP JP05066214A patent/JP3119961B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06256155A (en) | 1994-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU632289B2 (en) | Aqueous gel based on hyaluronic acid and desoxyribonucleic acid usable in cosmetics, and method for its preparation | |
| JPH01305012A (en) | Skin moisturizing composition and method for producing the same | |
| JP2003002813A (en) | Skin care composition | |
| US20100048886A1 (en) | Process for producing silylated pullulan and cosmetic preparation | |
| JPH05246837A (en) | Cosmetic | |
| WO2002051361A1 (en) | Skin cosmetics | |
| JP3119961B2 (en) | Stratum corneum turnover speed improver | |
| JP3558349B2 (en) | Whitening cosmetics | |
| JPH0782131A (en) | Hyaluronidase activity inhibitor and oil in water type cream base preparation | |
| JP3263409B2 (en) | External preparation for skin | |
| JPH0776513A (en) | Cosmetic for preventing skin aging | |
| JP2001261568A (en) | Production accelerator of profilaggrin and/or filaggrin protein | |
| JPS59130207A (en) | Corium and hair growth promoting cosmetic composition | |
| JPH07126143A (en) | Cosmetic | |
| FR2683720A1 (en) | Composition for cosmetic use containing particles of a gelled substance | |
| JP2002047119A (en) | Cosmetic | |
| JP3101090B2 (en) | External preparation for skin | |
| JPH07118135A (en) | Cosmetic | |
| WO2018115367A1 (en) | Use of rhamnolipids for the cosmetic treatment of skin redness | |
| EP3338763B1 (en) | Use of rhamnolipids for the cosmetic treatment of reactive skin | |
| US20030152599A1 (en) | Composition for external use | |
| JP2004107240A (en) | Skin care preparation for external use | |
| JPH0867617A (en) | Cosmetic | |
| JPH06128141A (en) | External agent for skin | |
| JP2001513815A (en) | Pharmaceutical or cosmetic compositions containing at least one retinoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091013 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101013 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111013 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121013 Year of fee payment: 12 |
|
| LAPS | Cancellation because of no payment of annual fees |